Participants ( mean age 59.8 years , HbA1c 8.4 % , FPG 7.9 mmol/L , BMI 25.4 kg/m ( 2 ) ) were randomised 2:1 to BID IDegAsp ( n = 282 ) or BIAsp 30 ( n = 142 ) and continued existing metformin treatment .